Ocuphire Pharma submits marketing application for eye drug, shares up

Opus Genetics

06/12/2022 14:08

** Ocuphire Pharma Inc  OCUP.O  shares rise 7.1% to $3.45
premarket
    ** Co submits marketing application to U.S. FDA for its
experimental eye disease treatment, mydriasis  urn:newsml:reuters.com:*:nGNX3Z6C2k
    ** If approved, OCUP's eye drug will to be the only
commercially available treatment for the reversal of mydriasis
    ** Drug developer's marketing application is based on data
involving 600 subjects in a mid-to-late stage study
    ** Up to Monday's close, stock had lost ~14% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))